Fluconazole in the treatment of candidiasis in immunocompromised children

C. Viscoli, E. Castagnola, F. Fioredda, B. Ciravegna, G. Barigione, A. Terragna

Research output: Contribution to journalArticle

73 Citations (Scopus)

Abstract

Fluconazole, a new triazole derivative, was evaluated in a pilot study of 34 episodes of candidiasis in 24 children. All the patients had predisposing conditions, such as human immunodeficiency virus infection, cancer, organ or bone marrow transplantation, neonatal age and malnutrition, and obstructive uropathy. The drug was administered at 6 mg/kg (body weight) once daily either orally or intravenously. Two patients with fungemia due to Candidaparapsilosis required an increased dosage of 12 mg/kg. Clinical and microbiological success was achieved in 30 of 34 cases (88%). Drug-related transaminase increases were observed in two cases (6%). Fluconazole may represent an effective alternative to amphotericin B in the treatment of candidiasis in children. Comparative trials are necessary to assess optimal dosages and efficacy.

Original languageEnglish
Pages (from-to)365-367
Number of pages3
JournalAntimicrobial Agents and Chemotherapy
Volume35
Issue number2
Publication statusPublished - 1991

Fingerprint

Fluconazole
Candidiasis
Fungemia
Triazoles
Amphotericin B
Virus Diseases
Transaminases
Bone Marrow Transplantation
Malnutrition
Pharmaceutical Preparations
Body Weight
HIV
Therapeutics
Neoplasms

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Fluconazole in the treatment of candidiasis in immunocompromised children. / Viscoli, C.; Castagnola, E.; Fioredda, F.; Ciravegna, B.; Barigione, G.; Terragna, A.

In: Antimicrobial Agents and Chemotherapy, Vol. 35, No. 2, 1991, p. 365-367.

Research output: Contribution to journalArticle

@article{9d39a0d0a7be49efa5db212aec513049,
title = "Fluconazole in the treatment of candidiasis in immunocompromised children",
abstract = "Fluconazole, a new triazole derivative, was evaluated in a pilot study of 34 episodes of candidiasis in 24 children. All the patients had predisposing conditions, such as human immunodeficiency virus infection, cancer, organ or bone marrow transplantation, neonatal age and malnutrition, and obstructive uropathy. The drug was administered at 6 mg/kg (body weight) once daily either orally or intravenously. Two patients with fungemia due to Candidaparapsilosis required an increased dosage of 12 mg/kg. Clinical and microbiological success was achieved in 30 of 34 cases (88{\%}). Drug-related transaminase increases were observed in two cases (6{\%}). Fluconazole may represent an effective alternative to amphotericin B in the treatment of candidiasis in children. Comparative trials are necessary to assess optimal dosages and efficacy.",
author = "C. Viscoli and E. Castagnola and F. Fioredda and B. Ciravegna and G. Barigione and A. Terragna",
year = "1991",
language = "English",
volume = "35",
pages = "365--367",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "2",

}

TY - JOUR

T1 - Fluconazole in the treatment of candidiasis in immunocompromised children

AU - Viscoli, C.

AU - Castagnola, E.

AU - Fioredda, F.

AU - Ciravegna, B.

AU - Barigione, G.

AU - Terragna, A.

PY - 1991

Y1 - 1991

N2 - Fluconazole, a new triazole derivative, was evaluated in a pilot study of 34 episodes of candidiasis in 24 children. All the patients had predisposing conditions, such as human immunodeficiency virus infection, cancer, organ or bone marrow transplantation, neonatal age and malnutrition, and obstructive uropathy. The drug was administered at 6 mg/kg (body weight) once daily either orally or intravenously. Two patients with fungemia due to Candidaparapsilosis required an increased dosage of 12 mg/kg. Clinical and microbiological success was achieved in 30 of 34 cases (88%). Drug-related transaminase increases were observed in two cases (6%). Fluconazole may represent an effective alternative to amphotericin B in the treatment of candidiasis in children. Comparative trials are necessary to assess optimal dosages and efficacy.

AB - Fluconazole, a new triazole derivative, was evaluated in a pilot study of 34 episodes of candidiasis in 24 children. All the patients had predisposing conditions, such as human immunodeficiency virus infection, cancer, organ or bone marrow transplantation, neonatal age and malnutrition, and obstructive uropathy. The drug was administered at 6 mg/kg (body weight) once daily either orally or intravenously. Two patients with fungemia due to Candidaparapsilosis required an increased dosage of 12 mg/kg. Clinical and microbiological success was achieved in 30 of 34 cases (88%). Drug-related transaminase increases were observed in two cases (6%). Fluconazole may represent an effective alternative to amphotericin B in the treatment of candidiasis in children. Comparative trials are necessary to assess optimal dosages and efficacy.

UR - http://www.scopus.com/inward/record.url?scp=0025973263&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025973263&partnerID=8YFLogxK

M3 - Article

C2 - 2024968

AN - SCOPUS:0025973263

VL - 35

SP - 365

EP - 367

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 2

ER -